Review anchor
Mitogen-activated protein kinase kinase kinase kinase 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Mitogen-activated protein kinase kinase kinase kinase 5
CHEMBL4852
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Mitogen-activated protein kinase kinase kinase kinase 5 as ChEMBL target CHEMBL4852, mapped to UniProt Q9Y4K4. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4852
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9Y4K4
Mitogen-activated protein kinase kinase kinase kinase 5
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Mitogen-activated protein kinase kinase kinase kinase 5 matters
Mitogen-activated protein kinase kinase kinase kinase 5 is reviewed as Mitogen-activated protein kinase kinase kinase kinase 5 (UniProt Q9Y4K4); the current evidence base includes 22 approved drugs, 1384 compounds, and 254 assays, with lead potency reaching pChEMBL 9.8.
Protein context
Mitogen-activated protein kinase kinase kinase kinase 5
Mitogen-activated protein kinase kinase kinase kinase 5 Sequence length is 846 aa.
Review this target as Mitogen-activated protein kinase kinase kinase kinase 5, mapped to UniProt Q9Y4K4. Sequence length is 846 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9Y4K4
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 22 approved drugs, 1384 compounds, and 254 assays for this target. The dominant activity type is KI. CHEMBL388978 is the current potency anchor at pChEMBL 9.8.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.8).
Activity source · ChEMBL 36 via Core Engine
22 approved
pChEMBL 9.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Mitogen-activated protein kinase kinase kinase kinase 5 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9Y4K4, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1384
Total Compounds
254
Total Assays
22
Approved Drugs
IC50: 36.0, KI: 679.0, EC50: 1.0, KD: 393.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL1996649
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL1999414
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL288441
|
9.5 | IC50 | Approved |
|
|
No preferred name
CHEMBL288441
|
9.3 | Kd | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
AXITINIB
CHEMBL1289926
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
Source Header